drugset / Trial / NCT02352311

Safety and Pharmacokinetic Characteristics of DKF-313

NCT02352311

Phase 1 Completed 54 enrolled Dongkook Pharmaceutical Co., Ltd.
RandomizedCrossoverOpen-labelOther

Summary

This is a randomized, open-label, single-dose, 2-treatment, 2-way, 2-period crossover study to evaluate the safety and the pharmacokinetic characteristics of DKF-313 (dutasteride and tadalafil) in healthy male volunteers.

Timeline

Start
2015-01
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dutasteride Small molecule 0.5 mg
Subject Tadalafil Small molecule 5 mg